中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

39 records (took 0.018 seconds)

    Clinical Decision Model
    2.
    发明申请
    Clinical Decision Model 审中-公开
    临床决策模型

    公开(公告)号：US20110295782A1

    公开(公告)日：2011-12-01

    申请号：US13123406

    申请日：2009-10-15

    Applicant: Alexander Stojadinovic ,  Eric A. Elster ,  Doug K. Tadaki ,  John S. Eberhardt, III ,  Trevor S. Brown ,  Thomas A. Davis ,  Jonathan Forsberg ,  Jason Hawksworth ,  Roslyn Mannon ,  Aviram Nissan

    Inventor： Alexander Stojadinovic ,  Eric A. Elster ,  Doug K. Tadaki ,  John S. Eberhardt, III ,  Trevor S. Brown ,  Thomas A. Davis ,  Jonathan Forsberg ,  Jason Hawksworth ,  Roslyn Mannon ,  Aviram Nissan

    IPC: G06F15/18

    CPC classification number: G16B40/00 ,  G16B25/00 ,  G16B50/00

    Abstract: An embodiment of the invention provides a method for determining a patient-specific probability of disease. The method collects clinical parameters from a plurality of patients to create a training database. A fully unsupervised Bayesian Belief Network model is created using data from the training database; and, the fully unsupervised Bayesian Belief Network is validated. Clinical parameters are collected from an individual patient; and, such clinical parameters are input into the fully unsupervised Bayesian Belief Network model via a graphical user interface. The patient-specific probability of disease is output from the fully unsupervised Bayesian Belief Network model and sent to the graphical user interface for use by a clinician in pre-operative planning. The fully unsupervised Bayesian Belief Network model is updated using the clinical parameters from the individual patient and the patient-specific probability of disease.

    Abstract translation: 本发明的实施例提供了一种用于确定患者特异性疾病概率的方法。 该方法从多个患者收集临床参数以创建训练数据库。 使用培训数据库中的数据创建完全无监督的贝叶斯信念网络模型; 并且，完全无监督的贝叶斯信仰网络得到验证。 从个体患者收集临床参数; 并且通过图形用户界面将这样的临床参数输入到完全无监督的贝叶斯信仰网络模型中。 患者特异性疾病概率从完全无监督的贝叶斯信念网络模型输出，并发送到图形用户界面，供临床医生在术前规划中使用。 使用来自个体患者的临床参数和患者特异性疾病概率来更新完全无监督的贝叶斯信仰网络模型。

    Hydrolysis Reactor for Hydrogen Production
    3.
    发明申请
    Hydrolysis Reactor for Hydrogen Production 有权
    氢生产水解反应器

    公开(公告)号：US20110052487A1

    公开(公告)日：2011-03-03

    申请号：US12874769

    申请日：2010-09-02

    Applicant: Thomas A. Davis ,  Michael A. Matthews

    Inventor： Thomas A. Davis ,  Michael A. Matthews

    IPC: C01B3/08

    CPC classification number: C01B3/065 ,  Y02E60/362

    Abstract: In accordance with certain embodiments of the present disclosure, a method for hydrolysis of a chemical hydride is provided. The method includes adding a chemical hydride to a reaction chamber and exposing the chemical hydride in the reaction chamber to a temperature of at least about 100° C. in the presence of water and in the absence of an acid or a heterogeneous catalyst, wherein the chemical hydride undergoes hydrolysis to form hydrogen gas and a byproduct material.

    Abstract translation: 根据本公开的某些实施方案，提供了化学氢化物的水解方法。 该方法包括向反应室中加入化学氢化物并将反应室中的化学氢化物暴露于水存在下至少约100℃的温度，并且在不存在酸或多相催化剂的情况下，其中 化学氢化物经历水解形成氢气和副产物。

    In vitro amplification/expansion of CD34.sup.+ stem and progenitor cells
    4.
    发明授权
    In vitro amplification/expansion of CD34.sup.+ stem and progenitor cells 失效
    CD34 +干细胞和祖细胞的体外扩增/扩增

    公开(公告)号：US5599703A

    公开(公告)日：1997-02-04

    申请号：US142569

    申请日：1993-10-28

    Applicant: Thomas A. Davis ,  Steven Kessler ,  Douglas H. Robinson

    Inventor： Thomas A. Davis ,  Steven Kessler ,  Douglas H. Robinson

    IPC: A61K35/12 ,  C12N5/0789 ,  C12N5/00 ,  A01N63/00 ,  A01N65/00

    CPC classification number: C12N5/0647 ,  A61K2035/124 ,  C12N2501/125 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2502/28

    Abstract: The present invention relates to a method of amplifying in vitro stemcells. In this method hematopoietic CD34.sup.+ stem and progenitor cells are isolated from human bone marrow and contacted with endothelial cells. The contacted stem cells and endothelial cells are cultured in the presence of at least one cytokine in an amount sufficient to support amplification/expansion of the hematopoietic CD34.sup.+ stem and progenitor cells. This method produces increased yields of hematopoietic CD34.sup.+ stem and progenitor cells which can be used in human therapeutics.

    Abstract translation: 本发明涉及一种放大体外干细胞的方法。 在这种方法中，造血CD34 +干细胞和祖细胞从人骨髓中分离并与内皮细胞接触。 在至少一种细胞因子存在下培养接触的干细胞和内皮细胞，其量足以支持造血CD34 +干细胞和祖细胞的扩增/扩增。 该方法产生可用于人类治疗剂的造血CD34 +干细胞和祖细胞的增加的产量。

    Replaceable thermal print head assembly
    5.
    发明授权
    Replaceable thermal print head assembly 失效
    可更换的热敏打印头组件

    公开(公告)号：US4896166A

    公开(公告)日：1990-01-23

    申请号：US175401

    申请日：1988-03-30

    Applicant: Robert A. Barker ,  Jonathan J. Burnard ,  Thomas A. Davis ,  Danny J. Prats ,  Melanie L. Seat

    Inventor： Robert A. Barker ,  Jonathan J. Burnard ,  Thomas A. Davis ,  Danny J. Prats ,  Melanie L. Seat

    IPC: B41J25/34

    CPC classification number: B41J25/34

    Abstract: A print head assembly includes the feature of snap-in, tool-less replaceability. The print head is intended for an application where extended use is expected and replacement, due to wear, will be necessary by nontechnical users of the printing system. In one embodiment, the print head utilizes two pins which slide into slots formed in the printer body. The print head is free to pivot about the two pins and is urged against a platen by the force of bias springs and a loaded pin. The loaded pin engages with, and forces upwrd on the heat-radiating fins extending from the bottom of the print head. Shelves formed in the printer body cover engage the two pins of the print head and force the print head, against the forces of the bias springs, into a proper alignment position when the cover is closed. This allows firm engagement of the print head with the platen, and proper alignment thereof, without fixing the print head to a mounting structure.

    Abstract translation: 打印头组件包括卡扣的功能，无需工具的可更换性。 打印头用于预期使用的应用程序，打印系统的非技术用户将需要由于磨损而更换。 在一个实施例中，打印头利用滑入到形成在打印机主体中的槽中的两个销。 打印头可自由地围绕两个销枢转，并通过偏置弹簧和加载销的力而抵靠压板。 加载的销与从打印头的底部延伸的散热片接合并且将其推向上。 形成在打印机主体盖中的搁板与打印头的两个销接合，并且当盖被关闭时将印刷头抵抗偏压弹簧的力压入适当的对准位置。 这允许打印头与压板的牢固接合以及其正确对准，而不将打印头固定到安装结构。

    Hydrolysis reactor for hydrogen production
    9.
    发明授权
    Hydrolysis reactor for hydrogen production 有权
    用于氢气生产的水解反应器

    公开(公告)号：US08323614B2

    公开(公告)日：2012-12-04

    申请号：US12874769

    申请日：2010-09-02

    Applicant: Thomas A. Davis ,  Michael A. Matthews

    Inventor： Thomas A. Davis ,  Michael A. Matthews

    IPC: C01B3/02 ,  C01B3/24

    CPC classification number: C01B3/065 ,  Y02E60/362

    Abstract: In accordance with certain embodiments of the present disclosure, a method for hydrolysis of a chemical hydride is provided. The method includes adding a chemical hydride to a reaction chamber and exposing the chemical hydride in the reaction chamber to a temperature of at least about 100° C. in the presence of water and in the absence of an acid or a heterogeneous catalyst, wherein the chemical hydride undergoes hydrolysis to form hydrogen gas and a byproduct material.

    Abstract translation: 根据本公开的某些实施方案，提供了化学氢化物的水解方法。 该方法包括向反应室中加入化学氢化物并将反应室中的化学氢化物暴露于水存在下至少约100℃的温度，并且在不存在酸或多相催化剂的情况下，其中 化学氢化物经历水解形成氢气和副产物。

    Inhibition of xenoreactive antibodies
    10.
    发明授权
    Inhibition of xenoreactive antibodies 失效
    抑制异反应性抗体

    公开(公告)号：US06572867B1

    公开(公告)日：2003-06-03

    申请号：US09292153

    申请日：1999-04-15

    Applicant: Alexander Schwarz ,  Guerard W. Byrne ,  Thomas A. Davis ,  Lisa E. Diamond ,  John S. Logan

    Inventor： Alexander Schwarz ,  Guerard W. Byrne ,  Thomas A. Davis ,  Lisa E. Diamond ,  John S. Logan

    IPC: A61K4726

    CPC classification number: C07K16/00 ,  A61K39/001 ,  A61K47/59 ,  A61K47/60 ,  A61K47/61 ,  A61K47/645 ,  A61K2039/6093

    Abstract: One aspect of the present invention relates to methods and compositions for attenuating xenograft rejection by administering, to an animal receiving the xenograft, an amount of a polymer-derivatized xenoantigen (hereinafter “xenopolymer”) effective for inhibiting or lessening the severity of hyperacute rejection response (HAR), or other immunological response to the graft, that is dependent on the presence of the xenoantigen on the grafted tissues or cells. In certain embodiments, the xenopolymer is administered in an amount sufficient to neutralize host antibodies (“xenoreactive antibodies” or “XNA”) immunoreactive with the xenoantigen. The xenopolymer may additionally, or alternatively, be used as a tolerogen (or anergen) for the xenoantigen, e.g., able to suppress, to some degree, the production/secretion of XNAs by the immune system of the host.

    Abstract translation: 本发明的一个方面涉及通过向接受异种移植物的动物施用一定量的有效抑制或减轻超急性排斥反应严重性的聚合物衍生的异种抗原（以下称为“异戊烯”）来减弱异种移植排斥的方法和组合物 （HAR）或其他对移植物的免疫应答，这取决于移植组织或细胞上异种抗原的存在。 在某些实施方案中，以足以中和与异种抗原免疫反应的宿主抗体（“异反应性抗体”或“XNA”）的量施用异种聚合物。 异源聚合物可以另外地或替代地用作异种抗原的耐受原（或过敏原），例如能够在一定程度上抑制宿主的免疫系统产生/分泌XNA。

Patent Agency Ranking